The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN299135     (2S,3aS,7aS)-1-[(2S)-2- [[(1S)-1...

Synonyms: CHEBI:288674, AC1O426Y
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of trandolapril


High impact information on trandolapril


Chemical compound and disease context of trandolapril


Biological context of trandolapril


Anatomical context of trandolapril


Associations of trandolapril with other chemical compounds


Gene context of trandolapril

  • CONCLUSION: These results suggest that attenuation in calpain-induced degradation of DRP complex is a possible mechanism for the Tra- or Can-mediated improvement of the pathogenesis of CHF following myocardial infarction [23].
  • Tra or Can treatment improved the hemodynamic parameters, attenuated changes in alpha-SG and dystrophin, and reversed both calpain contents and activities of the failing heart back to sham levels [23].
  • A significant and clear trend in variation with time of t-PA antigen was observed for the trandolapril group, but not for the placebo group [24].
  • In aortic tissue from CHF animals treated with the angiotensin-converting enzyme (ACE) inhibitor trandolapril, p38 MAP kinase phosphorylation was significantly reduced [25].
  • 2. Rats were orally treated with the ACE inhibitor trandolapril (3 mg kg(-1) day(-1)) or the AT1 receptor blocker L-158809 (1 mg kg(-1) day(-1)) from the 2nd to 8th week after CAL [26].

Analytical, diagnostic and therapeutic context of trandolapril

  • Diabetic animals treated with placebo and low-dose trandolapril weighed significantly less compared to the control group [27].
  • Twenty-four h after subtotal nephrectomy, rats were left untreated or started on treatment with the ET(A)-receptor antagonist LU 135252 (20 mg/kg per d) and with the angiotensin-converting enzyme (ACE) inhibitor trandolapril (0.3 mg/kg per d), respectively [28].
  • Consequences of overutilization and underutilization of thrombolytic therapy in clinical practice. TRACE Study Group. TRAndolapril Cardiac Evaluation [29].
  • In the TRAndolapril Cardiac Evaluation Study (TRACE) patients with reduced left ventricular systolic function were randomized 3-7 days post MI to receive either the ACE inhibitor trandolapril, or placebo [30].
  • During reperfusion trandolapril increased blood flow both in non-ischaemic and central ischaemic zones [17].


  1. Trandolapril in patients with left ventricular dysfunction after myocardial infarction. Neumayr, G., Gänzer, J. N. Engl. J. Med. (1996) [Pubmed]
  2. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. Køber, L., Torp-Pedersen, C., Carlsen, J.E., Bagger, H., Eliasen, P., Lyngborg, K., Videbaek, J., Cole, D.S., Auclert, L., Pauly, N.C. N. Engl. J. Med. (1995) [Pubmed]
  3. Trandolapril and human diabetic neuropathy. Bell, N., Hawkins, V., Holliman, D., Ikponmwosa, A., White, R. Lancet (1999) [Pubmed]
  4. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Malik, R.A., Williamson, S., Abbott, C., Carrington, A.L., Iqbal, J., Schady, W., Boulton, A.J. Lancet (1998) [Pubmed]
  5. Trandolapril decreases prevalence of ventricular ectopic activity in middle-aged SHR. Chevalier, B., Heudes, D., Heymes, C., Basset, A., Dakhli, T., Bansard, Y., Jouquey, S., Hamon, G., Bruneval, P., Swynghedauw, B. Circulation (1995) [Pubmed]
  6. Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Pepine, C.J., Handberg-Thurmond, E., Marks, R.G., Conlon, M., Cooper-DeHoff, R., Volkers, P., Zellig, P. J. Am. Coll. Cardiol. (1998) [Pubmed]
  7. Fixed combination trandolapril/verapamil sustained-release: a review of its use in essential hypertension. Muijsers, R.B., Curran, M.P., Perry, C.M. Drugs (2002) [Pubmed]
  8. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Schäfer, A., Fraccarollo, D., Hildemann, S., Christ, M., Eigenthaler, M., Kobsar, A., Walter, U., Bauersachs, J. Thromb. Haemost. (2003) [Pubmed]
  9. Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. Sanbe, A., Tanonaka, K., Kobayasi, R., Takeo, S. J. Mol. Cell. Cardiol. (1995) [Pubmed]
  10. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night? Buter, H., Hemmelder, M.H., van Paassen, P., Navis, G., de Zeeuw, D., de Jong, P.E. Nephrol. Dial. Transplant. (1997) [Pubmed]
  11. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. Fraccarollo, D., Galuppo, P., Hildemann, S., Christ, M., Ertl, G., Bauersachs, J. J. Am. Coll. Cardiol. (2003) [Pubmed]
  12. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Weir, M.R., Gray, J.M., Paster, R., Saunders, E. Hypertension (1995) [Pubmed]
  13. Failure of an ACE inhibitor to improve exercise tolerance. A randomized study of trandolapril. Trandolapril study group. Hampton, J.R., Cowley, A.J., Wnuk-Wojnar, A.M. Eur. Heart J. (1998) [Pubmed]
  14. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Song, J.C., White, C.M. Clinical pharmacokinetics. (2002) [Pubmed]
  15. Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Leighton, B., Sanderson, A.L., Young, M.E., Radda, G.K., Boehm, E.A., Clark, J.F. Diabetes (1996) [Pubmed]
  16. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Gross, M.L., El-Shakmak, A., Szábó, A., Koch, A., Kuhlmann, A., Münter, K., Ritz, E., Amann, K. Diabetologia (2003) [Pubmed]
  17. Chronic oral pretreatment with the angiotensin converting enzyme inhibitor, trandolapril decreases ventricular fibrillation in acute ischaemia and reperfusion. Muller, C.A., Opie, L.H., Peisach, M., Pineda, C.A. Eur. Heart J. (1994) [Pubmed]
  18. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Chobanian, A.V., Haudenschild, C.C., Nickerson, C., Hope, S. Hypertension (1992) [Pubmed]
  19. Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the stroke-prone rat. Münter, K., Hergenröder, S., Jochims, K., Kirchengast, M. J. Am. Soc. Nephrol. (1996) [Pubmed]
  20. Improving control of hypertension by an integrated approach -- results of the 'Manage it well!' programme. Szirmai, L.A., Arnold, C., Farsang, C. J. Hypertens. (2005) [Pubmed]
  21. Duration of inhibition of local microvascular ACE in spontaneously hypertensive rats. Vicaut, E., Hou, X. J. Hypertens. (1995) [Pubmed]
  22. Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). Galletti, F., Strazzullo, P., Capaldo, B., Carretta, R., Fabris, F., Ferrara, L.A., Glorioso, N., Semplicini, A., Mancini, M. J. Hypertens. (1999) [Pubmed]
  23. Effects of ACE inhibitor and AT1 blocker on dystrophin-related proteins and calpain in failing heart. Takahashi, M., Tanonaka, K., Yoshida, H., Oikawa, R., Koshimizu, M., Daicho, T., Toyo-Oka, T., Takeo, S. Cardiovasc. Res. (2005) [Pubmed]
  24. Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction. Pedersen, O.D., Gram, J., Jeunemaitre, X., Billaud, E., Jespersen, J. Coron. Artery Dis. (1997) [Pubmed]
  25. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent. Widder, J., Behr, T., Fraccarollo, D., Hu, K., Galuppo, P., Tas, P., Angermann, C.E., Ertl, G., Bauersachs, J. Cardiovasc. Res. (2004) [Pubmed]
  26. Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure. Yoshida, H., Takahashi, M., Tanonaka, K., Maki, T., Nasa, Y., Takeo, S. Br. J. Pharmacol. (2001) [Pubmed]
  27. Renal enlargement and insulin-like growth factor-1 accumulation in the Wistar rat model of experimental diabetes is not prevented by angiotensin converting enzyme inhibition. New, J.P., Canavan, J.P., Flyvbjerg, A., Hamon, G., Bilous, R.W., Marshall, S.M. Diabetologia (1996) [Pubmed]
  28. Endothelin A receptor blockade prevents capillary/myocyte mismatch in the heart of uremic animals. Amann, K., Münter, K., Wessels, S., Wagner, J., Balajew, V., Hergenröder, S., Mall, G., Ritz, E. J. Am. Soc. Nephrol. (2000) [Pubmed]
  29. Consequences of overutilization and underutilization of thrombolytic therapy in clinical practice. TRACE Study Group. TRAndolapril Cardiac Evaluation. Ottesen, M.M., Køber, L., Jørgensen, S., Torp-Pedersen, C. J. Am. Coll. Cardiol. (2001) [Pubmed]
  30. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies (as used in the TRACE study). TRAndolapril Cardiac Evaluation. Køber, L., Torp-Pedersen, C., Carlsen, J., Videbaek, R., Egeblad, H. Eur. Heart J. (1994) [Pubmed]
WikiGenes - Universities